Jay Gibbons
Harvard University Press(US)
Publications by Year
Research Areas
Neuroblastoma Research and Treatments, PI3K/AKT/mTOR signaling in cancer, Cancer, Hypoxia, and Metabolism, Chronic Lymphocytic Leukemia Research, Cancer Mechanisms and Therapy
Most-Cited Works
- → An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten+/−mice(2001)571 cited
- → Prognostic relevance of the mTOR pathway in renal cell carcinoma(2007)347 cited
- → Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity(2001)219 cited
- → In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model(2004)188 cited
- → Identification and Characterization of 4-[[4-(2-Butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3 S)thiomorpholinecarboxamide (TMI-1), a Novel Dual Tumor Necrosis Factor-α-Converting Enzyme/Matrix Metalloprotease Inhibitor for the Treatment of Rheumatoid Arthritis(2004)90 cited
- → Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment(2015)84 cited
- → Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402(2009)78 cited
- → Phaeosphaeride A, an Inhibitor of STAT3-Dependent Signaling Isolated from an Endophytic Fungus(2006)71 cited
- → Antitumor Efficacy Profile of PKI-402, a Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor(2010)59 cited
- → Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme(2004)55 cited